What to ask when looking for PRP care in Peoria

What to check before making the drive

The Peoria clinic is at 13128 N. 94th Drive, Suite 205, Peoria, AZ 85381. Old Town is roughly four miles away by 83rd Avenue and Thunderbird Road. Sun City is about two miles away along Thunderbird Boulevard. From Vistancia or Trilogy, your route may use Lake Pleasant Parkway, Bell Road and 91st Avenue. Ask whether you’ll return for another exam, procedure or follow-up.

One short drive may not be your whole schedule.

What to ask once you arrive

At QC Kinetix, a medical provider is a clinician who examines your joint and discusses office care. Regenerative options are treatments based on your own material, such as PRP concentrated from your blood. Bring any X-ray and a current medicine list. Ask how the PRP is prepared, what recovery involves and whether the total charge covers one procedure or all planned visits. Your exam may point to other care, and the clinician needs to say that plainly.

The exam matters more than the drive.

What to use as your measure

Choose the activity your soreness has limited. Maybe you want to walk the Ventana Lakes paths, play at Rio Vista or finish errands without resting. Tell the clinician exactly that. Joint preservation means exercise, braces and other care used to delay surgery. Knee or hip surgery alternatives mean choices that don’t involve an operation, and PRP may be one choice discussed. Nobody knows beforehand how much any option will help you.

Pick a result you’d notice in daily life.

Sources

1. The American Academy of Physical Medicine and Rehabilitation convened a technical expert panel that ran a structured literature review (2023, updated through June 2025) and a modified Delphi process, and issued five evidence-based clinical recommendations plus 11 consensus-based best practices for PRP in knee osteoarthritis. The statement is explicit that orthobiologic therapies 'remain an evolving area of practice' and that robust, dose-dependent randomized controlled trials are still needed to establish PRP's clinical effects.

   Borg-Stein J, Jayaram P, Colorado BS, et al. — AAPM&R guidance statement on platelet rich plasma for knee osteoarthritis. PM&R, 2026. DOI: 10.1002/pmrj.70144.

2. Medicare's national coverage policy covers autologous platelet-rich plasma ONLY for patients with chronic non-healing diabetic, pressure and/or venous wounds, and only within an approved coverage-with-evidence-development clinical study. There is no Medicare national coverage for PRP in osteoarthritis or tendinopathy, which is why these injections are billed to the patient as cash-pay.

   Centers for Medicare & Medicaid Services — Autologous Platelet-rich Plasma (Coverage with Evidence Development). CMS.gov, 2024.

3. The ESSKA-ICRS consensus applied the RAND/UCLA appropriateness method to 216 clinical scenarios for intra-articular PRP in knee OA. Only 84 scenarios (38.9%) were rated appropriate, 9 (4.2%) inappropriate and 123 (56.9%) uncertain. PRP was judged appropriate in patients aged 80 or under with KL grade 0-III osteoarthritis AFTER failed conservative non-injective or injective treatment; it was NOT considered appropriate as a first treatment, nor in KL grade IV (bone-on-bone) osteoarthritis, where 91.7% and 87.5% of scenarios respectively were uncertain.

   Kon E, de Girolamo L, Laver L, et al. — Platelet-rich plasma injections for the management of knee osteoarthritis: The ESSKA-ICRS consensus. Recommendations using the RAND/UCLA appropriateness method for different clinical scenarios. Knee Surgery, Sports Traumatology, Arthroscopy, 2024. DOI: 10.1002/ksa.12320.

4. A 24-site, 240-patient participant-blinded randomized trial of a single intratendinous PRP injection versus a sham (subcutaneous dry needle) for chronic midportion Achilles tendinopathy found VISA-A scores of 54.4 versus 53.4 at six months (adjusted mean difference -2.7; 95% CI -8.8 to 3.3) against a 12-point minimal clinically important difference. The authors stated the findings do not support the use of this treatment for chronic midportion Achilles tendinopathy.

   Kearney RS, Ji C, Warwick J, et al. — Effect of Platelet-Rich Plasma Injection vs Sham Injection on Tendon Dysfunction in Patients With Chronic Midportion Achilles Tendinopathy: A Randomized Clinical Trial. JAMA, 2021. DOI: 10.1001/jama.2021.6986.

5. In the RESTORE trial - the largest placebo-controlled PRP trial in knee osteoarthritis - 288 adults aged 50+ with symptomatic Kellgren-Lawrence grade 2-3 medial knee OA received three weekly intra-articular injections of leukocyte-poor PRP from a commercial system or saline placebo. At 12 months the mean change in knee pain was -2.1 points with PRP versus -1.8 with saline (difference -0.4; 95% CI -0.9 to 0.2; P=.17) against a minimum clinically important difference of 1.8, and the change in medial tibial cartilage volume was -1.4% versus -1.2% (difference -0.2%; 95% CI -1.9% to 1.5%; P=.81). Twenty-nine of 31 prespecified secondary outcomes showed no significant between-group difference. The authors concluded the findings do not support use of PRP for knee OA.

   Bennell KL, Paterson KL, Metcalf BR, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial. JAMA, 2021. DOI: 10.1001/jama.2021.19415.